Cefprozil dry suspension

This product is a second-generation cephalosporin drug with a broad-spectrum antibacterial effect. The bactericidal mechanism of this drug is to hinder the synthesis of bacterial cell walls. In vitro tests have shown that cefprozil has a significant effect on Gram-positive aerobic bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes, and has an inhibitory effect on Enterococcus tenacious, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus Warnei, Streptococcus agalactiae, Streptococcus C, D, F, G groups and Streptococcus viridans. It is ineffective against methicillin-resistant Staphylococcus and Enterococcus faecalis, and is highly sensitive to Gram-negative aerobic bacteria such as Haemophilus influenzae (including β-lactamase-producing strains) and Moraxella catarrhalis (including β-lactamase-producing strains); it can inhibit the growth of Citrobacter diversus, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae (including β-lactamase-producing strains), Proteus mirabilis, Salmonella, Shigella and Vibrio, and has no antibacterial effect on most strains of Acinetobacter, Enterobacter, Morganella morganii, Proteus vulgaris, Providencia and Pseudomonas. Cefprozil has a certain inhibitory effect on melanin Bacillus, Clostridium difficile, Clostridium perfringens, Fusobacterium, Streptococcus and Propionibacterium acnes among anaerobic bacteria, and has no antibacterial effect on most strains of Bacillus fragilis.

Cefprozil. Chemical name: (6R, 7R)-7-[(R)-2-amino-2-(p-hydroxy-phenyl)acetylamino]-8-oxo-3-propylene-5-thia-1-azabicyclo-(4,2,0)oct-2-ene-2-carboxylic acid monohydrate Molecular weight: C18H19N3O5S*H2O

This product is off-white to yellow granules and powder.

It is used for the following mild and moderate infections caused by sensitive bacteria: 1. Upper respiratory tract infection. 2. Lower respiratory tract infection. 3. Skin and skin soft tissue infection.

Oral administration: for adults with upper respiratory tract infection, 0.5g each time, once a day; for lower respiratory tract infection, 0.5g each time, twice a day; for skin or skin soft tissue infection, 0.5g per day, divided into 1 or 2 times; for severe cases, 0.5g each time, twice a day. For upper respiratory tract infection in children aged 2 to 12 years, take 7.5mg/kg once according to body weight, twice a day; for skin or skin soft tissue infection, take 20mg/kg once according to body weight, once a day. For otitis media in infants from 6 months to 12 years old, take 15mg/kg once according to body weight, twice a day; for acute sinusitis, generally take 7.5mg/kg once according to body weight, twice a day; for severe cases, take 15mg/kg once according to body weight, twice a day. The course of treatment is generally 7 to 14 days, but for acute tonsillitis caused by b-hemolytic streptococci,

1. The adverse reactions of ceftriaxone are similar to those of other oral cephalosporins, mainly gastrointestinal reactions, including diarrhea, nausea, vomiting and abdominal pain. Allergic reactions may also occur, most commonly rash and urticaria. Allergic reactions are more common in children than in adults, and often occur within a few days after the start of treatment and disappear within a few days after stopping the drug. Other adverse reactions are rare, including: Hepatobiliary system: AST and ALT increase. Occasionally, alkaline phosphatase and bilirubin increase. Cholestatic jaundice is rare. Central nervous system: dizziness, hyperactivity, headache, mental tension, insomnia. Occasionally, drowsiness. All these reactions are reversible. Blood system: leukopenia, eosinophilia. Kidney: increased serum urea nitrogen and increased serum creatinine. Others: diaper dermatitis-like rash and superinfection, genital itching and vaginitis. The following adverse events, regardless of whether their causal relationship with ceftriaxone has been clearly established, are rare in post-marketing monitoring. Allergy, angioneurotic edema, colitis, erythema multiforme, fever, serum sickness-like reaction, Stevens-Johnson syndrome and thrombocytopenia. 2. Adverse reactions of cephalosporins In addition to the adverse reactions listed above for the use of cefprozil, cephalosporins also have the following adverse reactions and cause laboratory abnormalities: aplastic anemia, hemolytic anemia, bleeding, renal insufficiency, toxic epidermal necrosis, toxic nephropathy, prolonged prothrombin time, positive Coomb test, increased LDH, pancytopenia, neutropenia, agranulocytosis. Several cephalosporin drugs are associated with epileptic seizures, especially when the dosage is not reduced in patients with renal impairment. If epileptic seizures are related to drug treatment, the drug should be discontinued and anticonvulsant treatment should be given according to clinical manifestations.

Patients who are allergic to this product or other cephalosporins are contraindicated.

Precautions for children: There is no data on the safety and efficacy of this drug in pediatric patients under 6 months old. However, there have been reports of other cephalosporins accumulating in newborns (due to the extended half-life of drugs in children of this age group). Precautions for pregnancy and lactation: 1. Use with caution in pregnant women. 2. A small amount of drug (<0.3% of the dose) can be detected in breast milk when a lactating woman takes 1g of this drug orally at one time. The average concentration over 24 hours is 0.25mg/L to 3.3mg/L. Since the effect of this drug on infants is not yet clear, lactating women should be cautious when taking this drug or stop breastfeeding. Precautions for the elderly: In the elderly (≥65 years old), the average area under the drug-time curve (AUC) of this drug increases by 35% to 60% relative to that of young adults. Elderly patients should adjust the dosage or medication interval according to their renal function under the guidance of a physician.

There have been reports of nephrotoxicity caused by the combination of aminoglycoside antibiotics and cephalosporins. The AUC of cefprozil can be doubled when used with probenecid. Drug/laboratory test interactions: Cephalosporin antibiotics can cause false positive reactions in urine glucose reduction test tablet reagents, but not in urine glucose enzymatic tests. This class of drugs can cause false negative blood glucose ferrocyanide reactions. Cefprozil in the blood does not interfere with the determination of creatinine in the blood or urine by the alkaline picrate method.

Keep away from light, seal tightly, and store in a cool and dry place (not exceeding 20℃).

Calculated as C18H19N3O5S 0.5g

24 months

Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd.

• Founded in:

  1987-09-10

• Address:

  No. 36, Taishan Road, Shantou City

• Tax NO.:

  91440500192729292G

• Registered Funds:

  83.98 million yuan

• Website:

  Log in to view

• Email:

  Log in to view